Onco360 Selected by Pfizer as Limited Distribution Pharmacy Provider

Onco360's industry-leading portfolio expanded to nearly 40 products.

Onco360, one of the nation’s largest independent providers of oncology pharmacy services, recently announced that it has been selected as a limited distribution pharmacy network participant by Pfizer Inc, and can immediately begin dispensing Bosulif (bosutinib), Inlyta (axitinib), Sutent (sunitinib), and Xalkori (crizotinib).

With the addition of these 4 medications, Onco360’s industry-leading oncology medication portfolio now comprises nearly 40 limited distribution products.

Each of the new additions to Onco360’s portfolio have been approved by the U.S. Food and Drug Administration (FDA) as targeted therapies in comprehensive cancer treatment:

• Bosulif, a treatment for chronic, accelerated, or blast phase Philadelphia chromosome positive chronic myelogenous leukemia in adult patients with resistance or intolerance to prior therapy.
• Inlyta, a treatment for advanced renal cell carcinoma in patients after failure of one prior systemic therapy.
• Sutent, a treatment for three forms of cancer, including advanced renal cell carcinoma, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors.
• Xalkori, a treatment for patients with metastatic ALK-positive non-small cell lung cancer.

“We are pleased to expand our relationship with Pfizer, and we look forward to collaborating on our shared goal of advancing innovative solutions to shape the future of cancer care,” said Paul Jardina, President and CEO of Onco360. “Our relationships with the leaders in pharmaceutical manufacturing, including Pfizer, are a critical component of Onco360’s mission to be the country’s most comprehensive source for oncology pharmacy and clinical support services.”

“Cancer care is complex and dynamic, and it requires a unique focus and dedication from a pharmacy practice standpoint,” said Burt Zweigenhaft, Vice Chairman and Chief Strategy Officer of Onco360. “At Onco360, we pride ourselves on providing our patients with robust treatment options, and the addition of these four drugs to our offering advances our mission of providing the highest level of support for cancer patients and the healthcare teams dedicated to their care.”

All four products are immediately available for order through Onco360. Information on how to order can be obtained by visiting http://www.Onco360.com/Order.

For more information about Onco360 please visit www.Onco360.com.

###

About Onco360, Oncology Pharmacy Solutions

With executive offices in New York City, Onco360 (http://onco360.com) is the largest independent provider of Oncology Pharmacy services in the country. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. The company’s clinical and dispensing model was developed specifically to meet the unique needs of oncology-treating physicians and their patients. Onco360 is advancing the continuum of oncology pharmaceutical care through patient advocacy, dispensing excellence, and the clinical experience and expertise that comes from its focus in oncology. Onco360 dispenses through its network JCAHO-accredited Oncology Pharmacies. PharMerica Corporation (NYSE:PMC), a leading institutional pharmacy, specialty infusion and hospital services company servicing healthcare facilities in the United States, made a significant strategic investment in Onco360. The partnership between PharMerica and Onco360 creates the only national oncology pharmacy and care management platform in the country, with the unique ability to service the localized needs of community- and hospital based-oncologists.

SOURCE: Onco360